Cellectar Biosciences (NASDAQ: CLRB) shares are surging more than 130% after the company lined up up to 140 million dollars in new financing. The funding was…
Rallybio (NASDAQ: RLYB) shares jumped after the company confirmed it will receive a 50 million dollar termination fee from a cancelled collaboration agreement. Even though the…
Prelude Corporation (PreludeDx), a precision‑diagnostics company focused on early‑stage breast cancer, received FDA Breakthrough Device designation for its AidaBREAST test. This is the company’s second Breakthrough Device;…
April 24, 2026
Nanosecond Pulses, Billion‑Dollar Market: Pulse Biosciences’ nsPFA Tech Takes Aim at AFib Heavyweights
Pulse Biosciences (NASDAQ: PLSE) is leaning hard into the pulsed‑field ablation (PFA) arms race, and its latest data suggest its nanosecond PFA platform (nsPFA) may…
Shares surge on extraordinary volume as CPIX sheds its commercial portfolio to bet on ifetroban Cumberland Pharmaceuticals (NASDAQ: CPIX) is transforming itself overnight. On Thursday,…
Medtronic (NYSE: MDT) has completed its acquisition of privately held CathWorks in a transaction valued at up to 585 million, including potential earn‑outs. The deal follows a 2022…
Kura Oncology (NASDAQ:KURA) saw its stock jump by 9% on Friday. Investors reacted strongly after the company released promising preliminary data from a recent kidney…
April 16, 2026
Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough
Revolution Medicines (NASDAQ: RVMD) just achieved a massive victory in a Phase 3 pancreatic cancer study. Following this clinical success, the California biotech doubled its…
April 13, 2026
Regeneron and Telix Forge $2.1 Billion Radiopharmaceutical Alliance for Cancer Treatment
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Telix Pharmaceuticals Limited officially finalized a strategic collaboration to develop and commercialize targeted radiopharmaceutical therapies for oncology. This partnership…
What Annovis Bio just announced Annovis Bio (NYSE: ANVS) shares sank about 25–30% after the company unveiled a discounted equity offering that materially dilutes existing holders….
April 07, 2026
Greenwich LifeSciences Files New GP2 Patent Claims That Could Double Its Breast Cancer Market
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has filed new patent claims for its breast cancer immunotherapy GLSI‑100 (GP2 + GM‑CSF), based on statistically significant immune‑response and recurrence‑rate…
Merit Medical Systems (NASDAQ: MMSI) is acquiring privately held View Point Medical in a deal valued at 140 million dollars, consisting of 90 million dollars upfront…